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ASSESSMENT OF R18,
COG1410, AND APP96-110
IN EXCITOTOXICITY AND
TRAUMATIC BRAIN INJURY
Abstract
Cationic arginine-rich and poly-arginine peptides (referred to as CARPs) have potent neuroprotective properties
in in vitro excitotoxicity and in vivo models of stroke. Traumatic brain injury (TBI) shares many pathophysiological
processes as stroke, including excitotoxicity. Therefore, we evaluated our lead peptide, poly-arginine R18, with
the COG1410 and APP96-110 peptides, which have neuroprotective actions following TBI. In an in vitro cortical
neuronal glutamic acid excitotoxicity injury model, R18 was highly neuroprotective and reduced neuronal
calcium influx, while COG1410 and APP96-110 displayed modest neuroprotection and were less effective at
reducing calcium influx. In an impact-acceleration closed-head injury model (Marmarou model), R18, COG1410,
and APP96-110 were administered intravenously (300 nmol/kg) at 30 minutes after injury in male SpragueDawley rats. When compared to vehicle, no peptide significantly improved functional outcomes, however the
R18 and COG1410 treatment groups displayed positive trends in the adhesive tape test and rotarod assessments.
Similarly, no peptide had a significant effect on hippocampal neuronal loss, however a significant reduction
in axonal injury was observed for R18 and COG1410. In conclusion, this study has demonstrated that R18 is
significantly more effective than COG1410 and APP96-110 at reducing neuronal injury and calcium influx
following excitotoxicity, and that both R18 and COG1410 reduce axonal injury following TBI. Additional dose
response and treatment time course studies are required to further assess the efficacy of R18 in TBI.
Keywords
• TBI • cationic arginine-rich peptides (CARPs) • R18 • APP96-110 • COG1410 • axonal injury • neuroprotection

Introduction
Neuroprotective pharmacological agents aimed
at minimising harm to the brain and improving
patient outcomes after a traumatic brain injury
(TBI) are currently lacking. As such, TBI places
a massive burden on society and the economy,
a situation further compounded by its rising
incidence [1]. Current surgical and rehabilitative
interventions are limited in their ability to
improve outcomes caused by TBI, and a large
proportion of survivors endure debilitating
neurological deficits as a consequence [2].
With limited efficacious treatment options, the
development of an effective neuroprotective
agent would be of great clinical significance in
terms of reducing the impact of TBI on patients
and the wider community.
Our laboratory has demonstrated that
cationic arginine-rich peptides including polyarginine peptides (hereafter referred to as

CARPs) have potent neuroprotective properties
in an in vitro glutamic acid excitotoxicity
neuronal injury model [3–6], as well as in vivo
after both permanent and transient middle
cerebral artery occlusion (MCAO) stroke in
rats [4,7–10]. Furthermore, increasing arginine
content and positive charge are critical for
peptide neuroprotective potency (Meloni et
al., 2015a), with poly-arginine peptide R18
identified as our lead peptide (18-mer of
arginine; Table 1). The COG1410 and APP96-110
peptides are derived from the apolipoprotein E
and amyloid precursor proteins, respectively,
and have been demonstrated to improve
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outcomes in several acute brain injury models,
including TBI [11–18]. Interestingly, both
COG1410 and APP96-110 are also cationic and
arginine-rich (Table 1).
In view of the involvement of excitotoxicity
in secondary central nervous system injury
cascades, and the pathophysiological parallels
between stroke and TBI, it is likely that CARPs
could also have beneficial effects following
TBI [19,20]. Therefore, we assessed our lead
peptide, R18, along with the COG1410 and
APP96-110 peptides in an in vitro glutamic acid
neuronal excitotoxicity injury model and an in
vivo impact-acceleration TBI model.

Table 1. Summary of peptides used in study.
Peptide

Sequence*

Net charge at pH 7

Purity

R18

H-RRRRRRRRRRRRRRRRRR-OH

+18

98%

APP96-110

Ac-NWCKRGRKQCKTHPH-NH2

+5

98%

COG1410

Ac-AS-Aib-LRKL-Aib-KRLL-NH2

+3

98%

*Aib = 2-Aminoisobutyric acid or 2-methylalanine

* E-mail: bruno.meloni@perron.uwa.edu.au
© 2017 Li Shan Chiu et al., published by De Gruyter Open.
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.
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Methods
Peptides used in this study
Details of the peptides used in this study are
provided in Table 1. Peptides for this study
were synthesised by Mimotopes (Australia)
and purified by high performance liquid
chromatography. For both in vitro and in vivo
studies, peptides were respectively prepared as
a 500 µM stock solution in water for irrigation
(Baxter, Australia), and in 0.9% sodium chloride
for injection (Pfizer, Australia). Reconstituted
peptides were stored at -20°C until use.

Primary cortical neuronal cultures
The isolation and culturing of primary cortical
neurons was undertaken as previously
described [3]. Briefly, cortical tissue extracted
from E18-19 Sprague-Dawley rats were
dissociated in Dulbecco’s modified Eagle
medium (DMEM; Life Technologies, Australia)
supplemented with 1.3 mM L-cysteine, 0.9
mM NaHCO3, 10 U/mL papain (Sigma Aldrich,
USA), 50 U/mL DNase (Sigma Aldrich), and
washed in cold DMEM/10% horse serum.
Neurons were resuspended in Neurobasal
media (Life Technologies, Australia) containing
2% B27 supplement (B27; Life Technologies)
and glutamine (0.5 mM), penicillin G (0.1 mg/
mL) and streptomycin (0.06 mg/mL). Neurons
were seeded into 96-well plastic plates
(Nunc, Australia) or 96-well glass wells (7 mm
diameter, ProTech, Australia) pre-coated with
poly-D-lysine (70 – 150 kDa; Sigma-Aldrich) and
maintained in a CO2 incubator (5% CO2, 95% air
balance, 98% humidity) at 37°C until use on days
in vitro 10 to 14. On day in vitro four the mitotic
inhibitor cytosine β-D-arabinofuranoside (1 µM;
Sigma-Aldrich) was added to the cultures to
inhibit the proliferation of non-neuronal cells.
Under these conditions, cultures routinely
consist of > 95% neurons and 1 - 3% astrocytes.

Glutamic acid excitotoxicity model
and peptide treatments
The glutamic acid model is routinely performed
on cortical neurons maintained in 96-well
plastic culture plates [3,4]. Peptides were added
to culture wells 10 minutes prior to glutamic
acid (L-glutamic acid; Sigma Aldrich) exposure
by removing media and adding 50 µL of MEM
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(Minimal Essential Medium; Life Technologies;
Cat. No.: 11090. Supplemented with glutamine,
penicillin G and streptomycin as above)/2%
B27 containing the specific peptide To induce
excitotoxicity, 50 µL of MEM/2% B27 containing
glutamate (200 µM; final concentration 100 µM)
was added to the culture wells and incubated
at 37°C in the CO2 incubator for 5 minutes
(note: peptide concentration reduced by half
during this step). Media in wells was then
replaced with 100 µL of MEM/2% B27 and
cultures incubated for a further 20 - 24 hours at
37°C in the CO2 incubator. For all experiments,
untreated controls with or without glutamic
acid treatment underwent the same incubation
steps and media additions. In this model,
neuronal survival following glutamic acid
treatment typically ranges from 2 - 10% (i.e. 90
- 98% cell death).

Neuronal viability assessment
Cell viability was examined with light
microscopy
to
qualitatively
assess
morphological cell death at 30 - 40 minutes
and 24 hours after glutamic acid exposure.
The MTS colorimetric viability assay (Promega,
Australia) was used to quantitatively assess
cell viability 24 hours after glutamic acid
exposure. The MTS assay quantifies the ability
of cytosolic enzymes in viable cells to reduce
the tetrazolium salt (MTS; 4,5-dimethyliazol2-yl)-5-(3-carboxymethoxy-phenyl)-2-(4sulfophenyl)-2H-tetrazolium salt) to the watersoluble brown formazan salt, which is detected
spectrophotometrically at 490 nm.

Intracellular calcium kinetics
Intracellular calcium influx was monitored
in neuronal culture wells (glass wells) using
Fura-2 AM (5 μM; Sigma Aldrich, Australia)
in real time using a fluorescent plate reader,
as previously described [5]. The aim of these
experiments was to determine the relative
change in intracellular calcium before and
after glutamic acid exposure. Briefly, cells
were loaded with the fluorescent calcium ion
indicator Fura-2 AM in 50 μL MEM/2% B27,
0.1% pluronic F-127 (Sigma-Aldrich), for 20
minutes at 37°C in the CO2 incubator. Fura-2
AM solution was removed from wells, replaced
with 50 μL MEM/2% B27 containing peptide

(1 or 5 μM) or NMDA/AMPA receptor blockers
(MK801/CNQX; 5 µM/5 µM; Tocris Bioscience,
UK) and incubated for 10 minutes at 37°C in
the CO2 incubator. Control cultures received 50
μL of MEM/2% B27 only. After the 10-minute
incubation period, media in wells was replaced
with 50 μL of balanced salt solution (mM: 116
NaCl, 5.4 KCl, 1.8 CaCl2, 0.8 MgSO4, 1 NaH2PO4;
pH 7.2) and wells were transferred to a
spectrophotometer (CLARIOstar, BMG Labtec,
Australia) while maintaining temperature at
37°C. Starting at 30 seconds prior to glutamic
acid addition (50 μL of 200 μM in MEM/2%
B27; final concentration 100 μM) to wells,
spectrophotometer measurements (excitation
355 nm/emission 495 nm) were recorded every
5 seconds until 2 minutes after glutamic acid
addition. Control wells did not receive glutamic
acid treatment. Experiments were performed
in triplicate. For fluorescent kinetic tracers,
data was converted to reflect proportional
neuronal calcium influx relative to both control
(no glutamic acid) and glutamic acid treated
control, with no glutamic acid control taken as
0% calcium influx (baseline) and glutamic acid
control treated as 100% calcium influx.

Traumatic brain injury model and
peptide administration
This study was approved by the Animal Ethics
Committee of the University of Western
Australia and follows the guidelines outlined
in the “Australian Code for the Care and Use of
Animals for Scientific Purposes”. Male SpragueDawley rats weighing 360 – 400 g were housed
under controlled conditions with a 12-hour
light-dark cycle and free access to food and
water ad libitum before and after surgery. A
total of 36 animals underwent the procedure,
but only 27 survived to the four-day end-point
(25% mortality). Nine peptide-treated animals
either died unexpectedly, or were euthanased
for welfare reasons as per the animal ethics
guidelines such as excessive weight-loss
(>15%), or persistent respiratory distress (see
Table 2 for details). Peptide-treatment groups
consisted of 4 – 5 animals, while sham and
vehicle treatment groups consisted of 5 and 8
animals, respectively.
The Marmarou weight-drop impactacceleration injury model [21] was adapted for
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Table 2. Summary of animal deaths following TBI.
Treatment

Reason for death

APP96-110

Died 2 days post-TBI: autopsy revealed subdural haematoma

APP96-110

Died 2 days post-TBI: animal displayed signs of respiratory distress prior to death

APP96-110

Died shortly after extubation following surgery: autopsy revealed possible lung pathology
(pneumonia)

APP96-110

Euthanased 2 days post-TBI due to excessive weight loss >15%

COG1410

Died at conclusion of surgery: animal did not regain spontaneous breathing

COG1410

Euthanased 2 days post-TBI due to respiratory distress

COG1410

Died 3 days post-TBI: autopsy revealed subarachnoid haemorrhage

R18

Euthanased 2 days post-TBI due to excessive weight loss >15%

R18

Euthanased 1 day post-TBI due to blood in urine: autopsy revealed testicular neoplasia

this study. Briefly, rats underwent anaesthesia
induction with 5% halothane (mix 30% O2/70%
N2O gas), intubated, and maintained using
1 - 2% halothane. To produce the injury, a 435 g
brass weight was dropped from a height of
180 cm, onto a steel disc (1 cm diameter and
2 mm thick) adhered to the skull of the rat with
cyanoacrylate. Just prior to the induction of
injury, the rat was placed prone and secured on
a foam bed, with masking tape across the upper
back and pelvic region on the dorsal surface.
The rat was then temporarily disconnected
from anaesthetic (< 1 min) to induce the injury.
Sham animals underwent the same surgical
and TBI procedures, but were placed adjacent
to the apparatus as the weight was released.
At 30 minutes post-impact, treatments
were administered intravenously (600 μL over
6 min) through the right internal jugular vein
using an infusion pump. Treatments consisted
of the vehicle control (0.9% NaCl for injection)
and R18, COG1410, and APP96-110 peptides
at 300 nmol/kg. Animals were randomised into
treatment groups, and all personnel carryingout animal and histological procedures were
blinded to treatments.

Post-surgical animal care and
monitoring
At the conclusion of surgery, pethidine (IM:
1 mg in 0.2 mL saline) and bupivacaine
were administered (SC: 0.1 mg in 0.2 mL
saline per site) to the head surgical wound.
A 2 mL volume of injectable saline was also
subcutaneously administered to aid hydration.
To avoid hypothermia, rat cages were placed on
a heating mat during post-surgical monitoring

and housed in a holding room maintained at 26
- 28°C. Post-surgery, animals were monitored
twice a day. Pethidine (SC: 1 mg in 0.2 mL saline)
was administered if the animal’s behaviour was
indicative of discomfort, and saline (SC: 2 mL) if
animal weight continued to decline. Rats were
also provided with sweetened nourishments to
encourage food intake.

Functional assessments
Due to the exploratory nature of the study,
three behavioural tests (Barnes maze, adhesive
tape removal, and rotarod) were assessed
to measure potential injury deficits. These
assessments were carried out daily, starting
at 24 hours after surgery and continued until
study end-point (4 days post-TBI). Each animal
was given three attempts at each test, and the
first attempt was used for statistical analyses.
The Barnes maze is a well-characterised
spatial learning and memory test [22] that
utilises a rat’s innate need to escape brightly-lit
areas. Animals are required to find the location
of an escape hole from 20 other holes set in a
round table top within 180 seconds. During the
test, a bright light is placed above the table to
serve as a mild aversion stimulus. The adhesive
tape test assesses sensorimotor function [23],
and has been previously used to detect deficits
in a similar model of TBI [24]. Alternating
between right and left forepaws, a 10 mm x
10 mm piece of adhesive tape (Diversified
Biotech, USA) is placed on the palmer surface
of the forepaw, and the time taken to remove
the tape recorded; animals were allowed 180
seconds to remove the tape. The rotarod test
is commonly used in experimental TBI [25],

and assesses vestibulomotor deficits. The test
involves placing the animal on a rotating rod
(Model number: MK-630B; Muromachi, Japan)
at a speed of four revolutions per minute (rpm),
increasing incrementally to 40 rpm; the time
that the animal remained on the rod is recorded
(maximum time allowable was 180 s).

Histological assessment for axonal
injury and hippocampal neuronal
loss
Rats were euthanased 4 days post-TBI
with pentobarbital (IP; 100 mg/kg) and
transcardially perfused with 200 mL of saline
followed by 200 mL of 10% neutral buffered
formalin. Brains were removed and post-fixed
in 4% formalin for 1 week before embedding
in paraffin. Brains were sectioned in 10 µm
coronal sections at approximately bregma
-4.5 for Bielschowsky’s silver staining, and
bregma -3.8 for Nissl staining. Stained sections
were imaged using light microscopy to assess
axonal injury within the corpus callosum and
neuronal loss in the cornu ammonis (CA) of the
hippocampus. The severity of axonal injury
was semi-quantitatively assessed in three
consecutive sections to obtain an overall grade,
ranging from 0 (indicating absence of injury) to
4, with increasing grade indicating increasing
levels of axons displaying disorganised
architecture, undulation and varicosities, and
disordered orientation of oligodendrocyte
nuclei. To determine the number of surviving
hippocampal neurons, CA1/CA2 and CA3
pyramidal neurons with an intact cell body
and the presence of an obvious nucleus and/or
nucleolus at 400X magnification were counted
in the entire length of both hippocampi using
Image J counter (v1.51j8; National Institutes
of Health, USA). Light microscopic images
were captured using an Olympus DP-70 digital
camera fitted to an Olympus IX70 inverted
microscope.

Statistical analysis
All statistical analyses were carried out using
SPSS (v.24; IBM, USA) and presented as mean
± standard error of the mean (SEM). Cell
viability, calcium kinetics measurements,
and CA counts were analysed by an analysis
of variance (ANOVA), followed by a Fisher
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post-hoc test. Area under the curve (AUC)
for calcium kinetics data was calculated by
trapezoidal approximation of the AUC using
fluorescent kinetic data obtained from 5 to
85 seconds after the addition of glutamic acid
to wells. Animal mortality was analysed using
Chi-square test. All functional and axonal injury
grading data were analysed by a Kruskal-Wallis
non-parametric test. For statistical purposes,
peptide treatment groups were compared to
the vehicle treatment group. A value of P < 0.05
was considered statistically significant.

Results
Effect of peptides on cultured
neurons exposed to glutamic acid
excitotoxicity
The neuroprotective dose response efficacy
of R18, COG1410, and APP96-110 peptides
was compared in cortical neuronal cultures
exposed to glutamic acid excitotoxicity (Figure
1). As previously reported [5], R18 was highly
neuroprotective following glutamic acid
excitotoxicity, achieving a 98% protective
effect at the 1 µM dose. In contrast, COG1410
and APP96-110 provided only modest
neuroprotection following glutamic acid
excitotoxicity, achieving approximately 10 - 15%
protection at the 1 and 10 µM dose, respectively.

Effect of peptides on neuronal
intracellular calcium kinetics
following glutamic acid excitotoxicity
The ability of R18, COG1410, and APP96-110
peptides at concentrations of 1 and 5 µM to
reduce neuronal intracellular calcium influx
following exposure to glutamic acid was
assessed using a Fura-2 AM calcium kinetics
assay (Figure 2a - d). At 1 and 5 μM, R18
significantly reduced neuronal intracellular
calcium influx (Figure 2a, d). Comparatively,
APP96-110 significantly reduced neuronal
calcium influx at 5 µM, but not at 1 µM, while
COG1410 displayed a non-significant reduction
in calcium influx at 5 µM.

Animal survival rate and weight loss
following TBI
All sham and vehicle-treated animals survived
to end of experiment day 4. In contrast, 2 of 7,
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Figure 1. Glutamic acid neuronal excitotoxicity model; peptide dose response experiments. Peptides present in
neuronal cultures for 10 minutes before and during the 5-min glutamic acid exposure. Neuronal viability measured 24 h following glutamic acid exposure. MTS data are expressed as percentage of neuronal viability, with no
insult and glutamic acid (Glut.) controls at 100% and 5%, respectively. Concentration of peptides are in μM. Data
are presented as mean ± SEM; N = 4; *P < 0.05 when compared to glutamic acid control.
3 of 9, and 4 of 9 animals in the R18 (P = 0.83),
COG1410 (P = 0.28) and APP96-110 (P = 0.18)
treatment groups respectively, did not survive
to day 4. Details regarding animal deaths
are summarised in Table 2. No significant
differences in weight loss were observed
between peptide and vehicle treatment groups
(data not shown).

Effect of peptides on functional
outcomes following TBI
When administered 30 minutes after injury,
R18, COG1410, and APP96-110 peptide
treatments did not result in any significant
improvements in functional outcomes when
compared to vehicle (Figures 3 - 5). Although
not statistically significant, R18 treatment
did improve functional measurements in
the adhesive tape (days 1 – 4; Figure 3a - d)
and rotarod (days 3 and 4; Figure 4c, d) tests.
Similarly, the COG1410 treatment group
displayed an improvement in the rotarod test
(day 4), but not to a statistically significant level.
In contrast, APP96-110 treatment appeared to
worsen Barnes maze performance (days 2 - 4;
Figure 5b - d).

Effect of peptides on histological
outcomes following TBI
Severity of axonal injury was significantly
reduced in the R18 (P = 0.02) and COG1410
(P = 0.05) treatment groups, while APP96-

110 had no effect on axonal injury (Figure
6). In the absence of injury, axons within
the corpus callosum appeared smooth
and well-organised, with oligodendrocyte
nuclei arranged parallel to axons (Figure 7a).
Following TBI, the architecture of callosal axons
showed varying degrees of disorganisation and
undulation and at times displayed varicosities,
with loss of the normal longitudinal orientation
of oligodendrocyte nuclei (Figure 7b - e).
Hippocampal CA neuronal loss was increased
in vehicle-treated animals compared to sham
animals, but not to a statistically significant
level (Figure 8).
Similarly, no significant
differences were observed in CA1/CA2 and
CA3 hippocampal counts between peptide and
vehicle treatment groups (Figure 8a, b).

Discussion
Following previous studies in our laboratory
demonstrating the neuroprotective efficacy
of CARPs, including our lead peptide R18 in in
vivo models of stroke [3–5,8–10], the present
study set out to determine if R18 could exert
beneficial effects in an in vivo model of TBI.
Two other peptides, COG1410 and APP96-110,
which have previously demonstrated positive
effects in in vivo TBI models were also included
for comparative purposes.
An initial in vitro glutamic acid neuronal
excitotoxicity study demonstrated R18 to be
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Figure 2. Intracellular calcium assessment using Fura-2 AM after glutamic acid exposure in cortical neuronal cultures. a – c: Fluorescent tracers; fluorescence intensity (FI) of

neuronal cultures 30 s before and after the addition (arrow) of glutamic acid (100 μM final concentration) expressed as a percentage of intracellular neuronal calcium influx.
Peptides (1 and 5 μM) and NMDA/AMPA receptor blockers (MK801/CNQX; 5 µM/5 µM) were added to neuronal cultures for 10 min and removed (time = 0) before glutamic
acid addition. Glutamic acid control received glutamic acid exposure only. Control did not receive peptide or glutamic acid treatment. d: Neuronal calcium influx expressed
as trapezoidal area under the curve (AUC). Data are presented as mean ± SEM; N = 3. * P < 0.05 when compared to glutamic acid control.

more neuroprotective and reduced neuronal
intracellular calcium influx to a greater degree
than both COG1410 and APP96-110. While
modest, the ability of COG1410 and APP96-110
to reduce excitotoxic neuronal calcium influx
is of interest, as these two peptides were not
designed based on this specific mechanism

of action. The modest inhibitory action of
COG1410 and APP96-110 on calcium influx is
likely due to their low cationic charge and the
presence of only two arginine residues. We have
previously demonstrated that CARPs can reduce
excitotoxic calcium influx [4,7,26], and that
calcium influx inhibition is influenced by peptide

cationic charge and arginine content [5,7].
In the in vivo study, administration of
R18, COG1410 and APP96-110 after TBI did
not appear to have any significant effects in
reducing CA neuronal loss, however CA injury
was modest, with vehicle-treated and sham
animals not recording significantly3different CA

151

Translational Neuroscience

Figure 3. Adhesive tape test measurements at days 1 - 4 (a - d) post-TBI. Peptide dose 300 nmol/kg. Sham (N = 5), vehicle (N = 8), APP96-110 (N = 5), COG1410 (N = 4), and
R18 (N = 5). Data are presented as mean ± SEM. There were no significant differences between vehicle and peptide treatment groups.

4
Figure 4. Rotarod measurements at days 1 - 4 (a - d) post-TBI. Peptide dose 300 nmol/kg. Sham (N = 5), vehicle (N = 8), APP96-110 (N = 5), COG1410 (N = 4), and R18 (N = 5).
Data are presented as mean ± SEM. There were no significant differences between vehicle and peptide treatment groups.
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Figure 5. Barnes maze measurements at days 1 - 4 (a - d) post-TBI. Peptide dose 300 nmol/kg. Sham (N = 5), vehicle (N = 8), APP96-110 (N = 5), COG1410 (N = 4), and R18 (N
= 5). Data are presented as mean ± SEM. There were no significant differences between vehicle and peptide treatment groups.

Axonal injury grade (0 – 4)

4

3

*

*

COG1410

R18

2

1

0

Sham

Vehicle

APP96-110

Treatment group
Figure 6. Axonal injury at day 4 post-TBI. Axonal injury grade of sham (N = 5), vehicle (N = 8), APP96-110 (N = 5),
COG1410 (N = 4), and R18 (N = 5) treatment groups. Peptide dose 300 nmol/kg. Data are presented as box plots
showing median and grade distribution; *P < .05 when compared to vehicle treatment group.

Figure 6

neuronal cell counts. In contrast to the results
obtained for hippocampal CA injury, R18 and
COG1410 significantly reduced axonal injury
following TBI, while APP96-110 was ineffective.
Diffuse axonal injury is a feature common
across all severities of traumatic brain injury

[27] and is caused by both mechanical and
chemical disturbances [28–31]. The mechanical
forces produce axonal stretching, while
chemical disruptions can induce glutamate
excitotoxicity, both of which lead to an increase
in neuronal intracellular calcium influx.

Furthermore, the toxic increase in neuronal
intracellular calcium can subsequently increase
mitochondrial calcium levels with detrimental
effects on the organelle, which ultimately
lead to cell death [31,32]. Consequently, given
the capacity of R18 and COG1410 to reduce
excitotoxicity-induced neuronal intracellular
calcium, in addition to the known ability of
CARPs to target and exert positive effects on
mitochondria [20,33,34], this could explain
the observed positive effects on axonal injury.
Furthermore, the reduced axonal injury in R18
and COG1410 treatment groups could explain
the trends in improved functional outcomes for
these treatments.
The peptides did not have any significant
effect on functional outcomes following TBI,
although some positive trends were observed
6
for R18 and COG1410 in the adhesive tape
and/or rotarod tests. The lack of significant
functional improvements most likely reflects
the low number of animals used and/or the
high variability associated with functional
outcomes after TBI. While the small sample
size is a limitation of the study, additional

153

Translational Neuroscience

animals were not recruited to the study for
several reasons: i) the study was considered
largely exploratory to establish experimental
procedures and uncover any initial evidence
of functional and/or histological treatment
effects; and ii) on animal welfare grounds
due to the unexpectedly high mortality rate
experienced in the peptide treatment groups,
particularly COG1410 and APP96-110.
Both COG1410 and APP96-110 peptides
have previously demonstrated the capacity to
reduce axonal injury and functional outcomes
following TBI [12,14]. However, APP96-110
was given intracerebroventricularly rather
than intravenously, which may account
for its lack of efficacy in the present study,
despite reducing in vitro excitotoxicityinduced neuronal intracellular calcium levels.
Intracerebroventricular
administration
of
APP96-110 represents a more direct route of
delivery into the brain and overcomes many
of the systemic pharmacokinetic interactions
that would reduce uptake into the brain if
administered intravenously such as the blood
brain barrier, elimination by the kidney and liver,
and degradation by vascular proteases. Similarly,
successful outcomes with COG1410 have been
achieved with higher doses [11,14,15,35] than
used in the present study. The 300 nmol/kg
dose was chosen in the present study because
R18 is neuroprotective at this dose following
MCAO [10], and to increase the possibility of
uncovering a differential treatment effect with

Figure 7. Representative images of axonal injury grading criteria from 0 – 4 (a – e) following Bielschowsky’s silver

stain, as indicated in the key. Examples of axons exhibiting undulated appearance and varicosities are designated
‘V’. Areas showing disordered arrangement of oligodendrocyte nuclei are designated ‘N’. Scale bar represents
100 μm.

Figure 8. Number of normal appearing CA neurons per millimetere of hippocampus at day 4 post-TBI. a: CA1/CA2; and b: CA3 regions at approximately bregma -3.8. Pep-

tide dose 300 nmol/kg. Data are presented as mean ± SEM. Sham (N = 5), vehicle (N = 8), APP96-110 (N = 5), COG1410 (N = 4), and R18 (N = 5). There were no significant
differences between sham, vehicle, and peptide treatment groups.
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R18, COG1410, and APP96-110.
Neuroprotection
by
the
APP96-110
peptide is purported to act mainly via its
heparin-binding activity [12], however its
exact mechanism has not been elucidated. A
similar peptide also derived from the amyloid
precursor protein suggests that APP96-110
could modulate calcium influx and activate
NFκβ transcription factors [36]. Similarly,
COG1410 may also affect calcium influx [37]
through interactions with cell-surface heparan
sulfate proteoglycans during internalisation
into the cell [38], but it is generally argued that
its neuroprotective action is mainly through
interactions with the lipoprotein receptorassociated protein [39]. In light of these
reports and the findings of the present study,
we propose that the neuroprotective and/or
calcium influx inhibitory activity of COG1410
and APP96-110 are mediated at least in part
by the positive charge and arginine content of
the peptides. In support of this, a more recent
CARP derived from selected non-sequential
amino acids from the same apolipoprotein E
region as COG1410 (CN-105; Ac-VSRRR-NH2,
charge +3) has demonstrated histological and
functional benefits in a closed-head TBI model
[40]. In addition, the CN-105 peptide has also

demonstrated efficacy in in vivo models of
stroke [41] and intracerebral haemorrhage [42].
While the in vivo study uncovered potential
therapeutic effects with R18 and COG1410,
several difficulties were encountered with the
animal functional assessment procedures.
With regards to the rotarod assessment, it was
observed that with repeated exposure, rats had
a tendency to leap off the rotating rod during
the test, leading to a shorter recorded latency.
This behaviour was observed in both sham
and injured rats. It was also observed that in
the Barnes maze test, the bright light became
a less effective aversion stimulus with rats
willing to explore the table rather than enter
the escape hole. Considering this, we suggest
additional functional tests and/or minimising
the exposure of animals to these tests in future
studies. For example, as an alternative learning
and memory test the Morris water maze may be
employed.
In conclusion, this study has demonstrated
that the CARP R18 is more effective than
either COG1410 or APP96-110 at reducing
neuronal death and calcium influx following
in vitro excitotoxicity. In addition, R18 showed
greater efficacy than APP96-110 in reducing
axonal injury and improving some functional

outcomes after TBI. Additional dose response
and therapeutic time window studies are
required to further evaluate the potential of
R18 as a neuroprotective therapy for TBI.
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